Investigating serum markers for predicting pregnancy complications
Investigation of First Trimester Serum Vasohibin-1, Vasohibin-2, Cardiotrophin-1 and Endocan Concentrations in Predicting Adverse Perinatal Outcomes
This study is testing if certain blood markers in pregnant women can help predict complications like preeclampsia and preterm birth during the early weeks of pregnancy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 88 (estimated) |
| Ages | 18 Years to 39 Years |
| Sex | Female |
| Sponsor | Umraniye Education and Research Hospital Government |
| Locations | 1 site (Istanbul, Ümraniye) |
| Trial ID | NCT06416995 on ClinicalTrials.gov |
What this trial studies
This observational study examines the relationship between maternal serum levels of vasohibin-1, vasohibin-2, cardiotrophin-1, and endocan during the 11th to 14th weeks of gestation and their association with adverse perinatal outcomes such as preeclampsia and preterm birth. The study builds on previous findings that these markers may play a role in vascular regulation and placental development. By analyzing serum concentrations, the researchers aim to identify potential predictive biomarkers for complications in low-risk pregnancies.
Who should consider this trial
Good fit: Ideal candidates for this study are low-risk pregnant women with singleton pregnancies who are undergoing first-trimester screening between 11 and 14 weeks.
Not a fit: Patients who are smokers, have multiple pregnancies, or have pregestational diseases will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to early identification of at-risk pregnancies, allowing for timely interventions to improve maternal and fetal outcomes.
How similar studies have performed: While the specific combination of biomarkers in this study may be novel, previous studies have indicated that similar approaches to predicting pregnancy complications have shown promise.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Those who had the first-trimester screening test between 11 and 14 weeks of pregnancy and are in the low-risk group * Those with singleton pregnancy * Those who did not conceive pregnancy with assisted reproductive treatment methods * Those who do not have any pregestational diseases * Those who do not have any uterine anomalies Exclusion Criteria: * Smokers * Those who are in the high-risk group with the first trimester screening test * Those with multiple pregnancies * Those who conceive with assisted reproductive treatment methods * Those who had any disease before pregnancy * Those who have any uterine anomalies
Where this trial is running
Istanbul, Ümraniye
- Ümraniye Eğitim ve Araştırma Hastanesi — Istanbul, Ümraniye, Turkey (Türkiye) (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.